Last Updated : Wednesday, April 1, 2020 20:03:16

News of Pharmaceuticals | Healthcare | Wellness in Gujarat

USFDA inspects Biocon’s Malaysian facility, issues EIR with VAI classification

BANGALORE / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Bengaluru headquartered Indian bio-technology company Biocon Ltd said of having got Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) for the company’s Malaysian facility, engaged in manufacturing insulin. The company statement attributed to the company spokesperson, titled,

STRIDE PHARMA’s Banglore facility gets EIR

BANGALORE / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Bangalore headquartered Stride Pharma Science Ltd said of having got Establishment Inspection Report (EIR) for their Bangalore facility after the facility was inspected by USFDA (US Food and Drugs Administration) in the month of January 2020, for specific

CADILA HEALTH gets USFDA nod to market tablets to treat Parkinson’s disease

AHMEDABAD / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) got USFDA (US Food and Drugs Administration) nod to market tablet to treat Parkinson’s disease or Parkinson’s like symptoms. In a company press-release titled, “Zydus receives

GLENMARK PHARMA gets USFDA nod to market for oral diabetic medicine

MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Mumbai headquartered pharmaceutical products manufacturing company Glenmark Pharmaceuticals Ltd said of having got tentative approval from USFDA (US Food and Drugs Administration) to sell and market treatment to cure diabetic in form of oral diabetic medicine – Dapagliflozin Tablets, in

Dr REDDY’s LAB launches injection to treat narcotic overdose

HYDERABAD / PRINCETON (NEW JERSEY – US) / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered Indian Pharmaceutical products manufacturing company Dr Reddy’s Laboratories Ltd said of having announced first-to-market launch of Naloxone Hydrochloride Injection USP in 2 mg (milligram) / 2 ml (milliliter) dosage value,

Dr REDDY’s LAB gets USFDA nod to market injection to treat severe agitation in patients with schizophrenia

HYDERABAD / PRINCETON / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered pharmaceutical products manufacturing company Dr Reddy’s Laboratories Ltd said of having got nod from USFDA (US Food and Drugs Administration) to sell injection in US Market to treat severe agitation in patients with schizophrenia, the

BLISS GVS PHARMA completes commissioning of Phase-1 @ Palghar facility

MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Mumbai headquartered pharmaceutical products manufacturing company Bliss GVS Pharma Ltd said of having completed commissioning and qualification of Phase-I of the multi-product manufacturing facility situated at Palghar in East Maharashtra. For LONG READ, please click / log on / visit

#DLGEXCLUSIVE / GUJARAT GOVT’s Health Dept differs on CORONA (COVID-19) data & numbers

GANDHINAGAR / AHMEDABAD / RAJKOT – In a communication issued by top bureaucrats from Health Department of Gujarat Government, it seems that senior officials are either not synced or not well-informed on the data and numbers of the people infected due to Corona Virus (COVID-19) across the world as well as number of people infected

INFOSYS Study says, “Key Workplace Transformation Decisions Shifting”

(File Picture) Infosys ranked as number one employer in Middle East

BANGALORE / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Bengaluru headquartered Information Technology major Infosys Ltd said that the study undertaken by the company indicates of key workplace transformation decisions are shifting from CHROs (Chief Human Resource Officers) to CEOs (Chief Executive Officers), the company surveyed more

USFDA Accepts BLA for Mylan and Biocon’s Proposed Biosimilar for Review

BENGALURU / HERTFORDSHIRE (PITTSBURGH) / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Bengaluru headquartered biotechnology company Biocon Ltd said of USFDA having accepted BLA (Biologics License Application) for a proposed biosimilar Bevacizumab, for review. For LONG READ, please click / log on / visit :- https://datelinegujarat.blogspot.com In

GRANULES INDIA gets USFDA nod to sell drug to treat potassium deficiency

HYDERABAD / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered pharmaceutical products manufacturing company Granules India Ltd said of having got USFDA nod to market drug to treat potassium deficiency – Potassium Chloride Extended – Release Tablets USP in dosage value of 600 mg (milligram) and

VIMTA LABS completes acquisition of EMTAC LABS

HYDERABAD / MUMBAI / RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered healthcare services provider company Vimta Labs Ltd said of having completed acquisition of Emtac Laboratories with four months of the announcement which company had made on November 9, 2019 after acquiring 3.4 million (~34,16,500) shares of

STRIDES PHARMA gets USFDA nod to market anti-bacterial treatment

BANGALORE / MUMBAI – In a regulatory update submitted to the Indian Stock Exchanges, Bangalore headquartered Strides Pharma Science Ltd said of having got nod from USFDA (US Food and Drugs Administration) to market anti-bacterial treatment drug Tetracycline Hydrochloride Capsules in 250 mg (milligram) and 500 mg dosage. For LONG READ, please click / log

USFDA inspection @ AUROBINDO PHARMA’s Unit IV continues …

HYDERABAD | MUMBAI | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad headquartered Aurobindo Pharma Ltd said of the USFDA inspection still open and under review of the company’s Unit IV, as per the communication received from the US Food and Drugs Administration, as per the previous communication, the

STRIDES PHARMA to acquire 18 ANDAs from Pharmaceutics International, Inc.

BENGALURU | MUMBAI | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Bengaluru headquartered Indian Pharmaceutical products manufacturing company Strides Pharma Science Ltd said of having acquired 18 abbreviated new drug applications (ANDA) from Pharmaceutics International, Inc., for a transaction value of approximately US Dollars $6.1 million, of which US

GRANULES INDIA gets USFDA nod to market tablets to treat joint pains and fever

HYDERABAD | MUMBAI | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Hyderabad (Telangana) headquartered Indian Pharmaceuticals company Granules India Ltd said of USFDA having got approval from USFDA (US Food and Drugs Administration) to market tablets to treat joint pains and fever. For LONG READ click / log on

Do NOT follow this link or you will be banned from the site!